Navigation Links
Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Date:1/6/2009

CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis). FAP is an inherited gastrointestinal disease that causes hundreds of polyps to form in the colon. Today, without prophylactic removal of the colon, people with FAP almost inevitably develop colon cancer, and there is no medical treatment available. Cequent will present its findings, the first-ever proof of activity of an oral RNAi drug in non-human primates, in a poster at the Keystone Symposia Conference, Therapeutic Modulation of RNA Using Oligonucleotides. The conference will be held February 8 - 13 in Lake Louise, Alberta Canada.

"Delivery of RNAi into the targeted cells and tissues remains one of the biggest challenges in the development of RNAi-based therapeutics - a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease," said Cequent President and CEO, Peter Parker. "We have shown previously in cell-culture assays and in a mouse model for human colon cancer that our tkRNAi technology effectively suppresses beta-catenin, a key oncogene in FAP. These new results are very encouraging, and represent another significant milestone in our work to turn the promise of RNAi into safe and effective therapies to treat devastating diseases, like FAP, and improve the lives of those affected."

The study showed that tkRNAi targeting beta-catenin was well tolerated at high dosing levels, with no product-related adverse events, no increase in serum cytokines, and no gross or histopathologic abnormalities noted. Ora
'/>"/>

SOURCE Cequent Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)...  Volcano Corporation (Nasdaq: VOLC ), ... economic outcomes on a global basis by developing ... visualization, physiology diagnostics and therapies, today confirmed receipt ... from Engaged Capital, LLC.  The Company issued the ... welcomes the perspectives of its shareholders, and has ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... Summary GlobalData,s new report, "EU5 Esophagoscopes ... market data on the EU5 Esophagoscopes & Gastroscopes ... US dollars, volume (in units) and average prices ... Video Esophagoscopes, Flexible Non-Video (Fibre) Gastroscopes and Flexible ...
(Date:9/29/2014)... 29, 2014  Cancer Treatment Institute of ... new drug treatment: a carefully formulated, first-of-its-kind combination ... proven successful at treating multiple types of cancer. ... treatment are optimistic that it could significantly improve ... therapeutic avenues. "These two drugs are ...
Breaking Medicine Technology:Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 3Cancer Treatment Institute of Colombia Demonstrates Unprecedented Results Using Unique Cancer Drug Combination of 3-Bromopyruvate and Salinomycin for Treatment of Multiple Types of Cancer 2Cancer Treatment Institute of Colombia Demonstrates Unprecedented Results Using Unique Cancer Drug Combination of 3-Bromopyruvate and Salinomycin for Treatment of Multiple Types of Cancer 3
... GPRO ) announced today that the Company ... investigational APTIMA(R) assay to detect human,papillomavirus (HPV), which ... multi-center study was an important goal,for Gen-Probe in ... and,chief operating officer. "Enrolling our first patient last ...
... Alone and in combination with, Ramipril Global Endpoint ... Annual Scientific Session of the American College of ... online in the New England Journal of Medicine, ... the landmark,ONTARGET(TM) trial have demonstrated that MICARDIS(R) (telmisartan), ...
Cached Medicine Technology:Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 2Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 3Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 4Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 5Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 2Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 3Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 4Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 5Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 6Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 7
(Date:9/30/2014)... September 30, 2014 For Dr. Jim Pertsch, ... in San Mateo, CA, the decision was simple. “I was ... when I heard Miele offered a solution for cleaning surgical ... for ways to help the staff, and the Miele system ... and I don’t worry as much about the staff coming ...
(Date:9/30/2014)... CE-Classes.com has announced the addition of ... for Healthcare Providers. This course on treating tobacco addiction ... - substance abuse counselors, social workers, professional counselors, psychologists, ... implementation of this new course” said Ron Black, president ... smoking has tremendous value to our society.” , Appropriate ...
(Date:9/29/2014)... September 30, 2014 Shoulder pain is one ... with persistent shoulder pain generates nearly ¾ of the total ... of all adults will experience shoulder pain, and of those ... also been reported that 1 in 4 people with either ... than a year. , “This is a real problem, not ...
(Date:9/29/2014)... 30, 2014 Foundations Recovery Network, an ... the start of its 40th national conference by hosting ... a featured keynote speaker at the Moments of Change ... in the fields of addiction and mental health treatment. ... Fla., September 29 – October 2, 2014, at The ...
(Date:9/29/2014)... Boston, MA A retrospective study led by ... found an overuse of colonoscopies for colorectal cancer ... commonly recommended shorter follow-up intervals than established guidelines ... subsequent colonoscopy overuse. , "Our study shows ... being performed too early, resulting in use of ...
Breaking Medicine News(10 mins):Health News:Introducing a Safe, Time-Saving Solution for Ambulatory Surgery Centers 2Health News:Introducing a Safe, Time-Saving Solution for Ambulatory Surgery Centers 3Health News:CE-Classes.com Introduces New Online Course for Healthcare Providers 2Health News:CE-Classes.com Introduces New Online Course for Healthcare Providers 3Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Endoscopists recommend frequent colonoscopies, leading to its overuse 2
... , , WASHINGTON, July 9 The ... the work of the National Organization on Disability,s (N.O.D.) ... emergency managers and the disability community as the only ... and personnel experienced in emergency management and disability issues. ...
... 9 The ongoing recession and associated job cuts ... employee benefit plans, slowing health insurer growth and pressuring ... and Consulting. , , "Conning projects that health ... resulting in deteriorating margins through 2011," said Terence Martin, ...
... Hospital for Special Surgery have shown that a biodegradable scaffold ... knee cartilage. The study is unique in that it used ... to examine how the plug incorporated itself into the knee. ... meeting of the American Orthopedic Society for Sports Medicine, June ...
... ... the world,s leading manufacturer and distributor of automated blood pressure monitors and health testing ... ... 2009 -- Lifeclinic International has named Lon von Hurwitz Executive Vice President ...
... externally , THURSDAY, July 9 (HealthDay News) -- U.S. ... ear infections in children. , Antibiotics are typically used ... for children with recurrent ear infections. , "The emergence ... surgical procedure raise the need to develop different ways ...
... 9 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... devices worldwide, today announced that it will report its,financial ... after the U.S.,market closes on August 10, 2009. Mindray,s ... on August 11, 2009 U.S. Eastern Time (8:00 PM ...
Cached Medicine News:Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 3Health News:Conning Research: Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011 2Health News:Study identifies potential fix for damaged knees 2Health News:Study identifies potential fix for damaged knees 3Health News:Pioneer of Digital Place-Based Media Joins World's Leading Blood Pressure and Health Kiosk Manufacturer 2Health News:Vaccine May Someday Thwart Ear Infections 2Health News:Mindray to Report Second Quarter 2009 Financial Results on August 10, 2009 2
Curved shaft with flat 4.5 mm hook. Flat serrated handle with polished finish. Overall length: 5.3 inches....
... device allows for quick and ... ophthalmic surgical procedures. The "Quick ... through which a suture may ... during the loading procedure. The ...
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
Left angled 5 mm blunt hook. Overall length: 9.9 inches....
Medicine Products: